![](https://webarchive.library.unt.edu/eot2008/20090509180140im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090509180140im_/http://www.cancer.gov/images/spacer.gif)
vandetanib An orally bioavailable 4-anilinoquinazoline. Vandetanib
selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090509180140im_/http://www.cancer.gov/images/spacer.gif)
US brand name: | ![](https://webarchive.library.unt.edu/eot2008/20090509180140im_/http://www.cancer.gov/images/spacer.gif) | Zactima | | ![](https://webarchive.library.unt.edu/eot2008/20090509180140im_/http://www.cancer.gov/images/spacer.gif) | Code names: | ![](https://webarchive.library.unt.edu/eot2008/20090509180140im_/http://www.cancer.gov/images/spacer.gif) | AZD6474 ZD6474 | | ![](https://webarchive.library.unt.edu/eot2008/20090509180140im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090509180140im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509180140im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509180140im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090509180140im_/http://www.cancer.gov/images/spacer.gif) |